Cryo Cell International Inc: Form 10-Q for the period ended Aug 31, 2022
Filed with the SEC on Oct 18, 2022 and accepted by EDGAR at Oct 18, 2022, 00:31 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-08-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-06-01 to 2022-08-31 | $7.7m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months2021-12-01 to 2022-08-31 | $22.6m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2022-06-01 to 2022-08-31 | $2.3m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2021-12-01 to 2022-08-31 | $6.7m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2022-06-01 to 2022-08-31 | $80.3k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2021-12-01 to 2022-08-31 | $308.4k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2022-06-01 to 2022-08-31 | $3.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2021-12-01 to 2022-08-31 | $10.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-06-01 to 2022-08-31 | $954.3k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2021-12-01 to 2022-08-31 | $3.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-06-01 to 2022-08-31 | $365.3k | us-gaap:InterestExpense |
| Interest expense | 9 months2021-12-01 to 2022-08-31 | $948.0k | us-gaap:InterestExpense |
| Income tax | 3 months2022-06-01 to 2022-08-31 | $174.1k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2021-12-01 to 2022-08-31 | $762.9k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-06-01 to 2022-08-31 | $466.8k | us-gaap:NetIncomeLoss |
| Net income | 9 months2021-12-01 to 2022-08-31 | $1.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-06-01 to 2022-08-31 | $0.06 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2021-12-01 to 2022-08-31 | $0.23 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-06-01 to 2022-08-31 | $0.06 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2021-12-01 to 2022-08-31 | $0.23 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-06-01 to 2022-08-31 | 8,404,485 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2021-12-01 to 2022-08-31 | 8,475,661 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2021-12-01 to 2022-08-31 | $6.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2021-12-01 to 2022-08-31 | $12.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2021-12-01 to 2022-08-31 | $1.7m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-08-31 | $2.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-08-31 | $11.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-08-31 | $66.8m | us-gaap:Assets |
| Current liabilities | At period end2022-08-31 | $23.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-08-31 | $69.2m | us-gaap:Liabilities |
| Long-term debt | At period end2022-08-31 | $8.8m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2022-08-31 | −$2.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-22-019626. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.